source
- Outpace Bio halts Phase 1 ovarian cancer CAR‑T trialOutpace Bio announced that it has stopped its Phase 1 trial of OPB-101, an autologous CAR‑T therapy targeting mesothelin in ovarian cancer. The company said the trial will no longer enroll patient…
- FDA officials share guidance on de novo device classifications and upcoming MDUFA VI changes at MedTech ConferenceAt the MedTech Conference in Boston, FDA officials and industry experts discussed de novo classification requests. They offered practical tips for companies seeking de novo designation, stressing…